Polycystic Ovary by Sonography
Find information on thousands of medical conditions and prescription drugs.

Polycystic ovarian syndrome

Polycystic ovary syndrome (PCOS, also known clinically as Stein-Leventhal syndrome), is an endocrine disorder that affects 5–10% of women. It occurs amongst all races and nationalities, is the most common hormonal disorder among women of reproductive age, and is a leading cause of infertility. The symptoms and severity of the syndrome vary greatly between women. While the causes are unknown, insulin resistance (often secondary to obesity) is heavily correlated with PCOS. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Arthritis
Arthritis
Bubonic plague
Hypokalemia
Pachydermoperiostosis
Pachygyria
Pacman syndrome
Paget's disease of bone
Paget's disease of the...
Palmoplantar Keratoderma
Pancreas divisum
Pancreatic cancer
Panhypopituitarism
Panic disorder
Panniculitis
Panophobia
Panthophobia
Papilledema
Paraganglioma
Paramyotonia congenita
Paraphilia
Paraplegia
Parapsoriasis
Parasitophobia
Parkinson's disease
Parkinson's disease
Parkinsonism
Paroxysmal nocturnal...
Patau syndrome
Patent ductus arteriosus
Pathophobia
Patterson...
Pediculosis
Pelizaeus-Merzbacher disease
Pelvic inflammatory disease
Pelvic lipomatosis
Pemphigus
Pemphigus
Pemphigus
Pendred syndrome
Periarteritis nodosa
Perinatal infections
Periodontal disease
Peripartum cardiomyopathy
Peripheral neuropathy
Peritonitis
Periventricular leukomalacia
Pernicious anemia
Perniosis
Persistent sexual arousal...
Pertussis
Pes planus
Peutz-Jeghers syndrome
Peyronie disease
Pfeiffer syndrome
Pharmacophobia
Phenylketonuria
Pheochromocytoma
Photosensitive epilepsy
Pica (disorder)
Pickardt syndrome
Pili multigemini
Pilonidal cyst
Pinta
PIRA
Pityriasis lichenoides...
Pityriasis lichenoides et...
Pityriasis rubra pilaris
Placental abruption
Pleural effusion
Pleurisy
Pleuritis
Plummer-Vinson syndrome
Pneumoconiosis
Pneumocystis jiroveci...
Pneumocystosis
Pneumonia, eosinophilic
Pneumothorax
POEMS syndrome
Poland syndrome
Poliomyelitis
Polyarteritis nodosa
Polyarthritis
Polychondritis
Polycystic kidney disease
Polycystic ovarian syndrome
Polycythemia vera
Polydactyly
Polymyalgia rheumatica
Polymyositis
Polyostotic fibrous...
Pompe's disease
Popliteal pterygium syndrome
Porencephaly
Porphyria
Porphyria cutanea tarda
Portal hypertension
Portal vein thrombosis
Post Polio syndrome
Post-traumatic stress...
Postural hypotension
Potophobia
Poxviridae disease
Prader-Willi syndrome
Precocious puberty
Preeclampsia
Premature aging
Premenstrual dysphoric...
Presbycusis
Primary biliary cirrhosis
Primary ciliary dyskinesia
Primary hyperparathyroidism
Primary lateral sclerosis
Primary progressive aphasia
Primary pulmonary...
Primary sclerosing...
Prinzmetal's variant angina
Proconvertin deficiency,...
Proctitis
Progeria
Progressive external...
Progressive multifocal...
Progressive supranuclear...
Prostatitis
Protein S deficiency
Protein-energy malnutrition
Proteus syndrome
Prune belly syndrome
Pseudocholinesterase...
Pseudogout
Pseudohermaphroditism
Pseudohypoparathyroidism
Pseudomyxoma peritonei
Pseudotumor cerebri
Pseudovaginal...
Pseudoxanthoma elasticum
Psittacosis
Psoriasis
Psychogenic polydipsia
Psychophysiologic Disorders
Pterygium
Ptosis
Pubic lice
Puerperal fever
Pulmonary alveolar...
Pulmonary hypertension
Pulmonary sequestration
Pulmonary valve stenosis
Pulmonic stenosis
Pure red cell aplasia
Purpura
Purpura, Schoenlein-Henoch
Purpura, thrombotic...
Pyelonephritis
Pyoderma gangrenosum
Pyomyositis
Pyrexiophobia
Pyrophobia
Pyropoikilocytosis
Pyrosis
Pyruvate kinase deficiency
Uveitis
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Nomenclature

Other names for this disorder include:

  • Polycystic ovary disease (although this is not correct, as PCOS is characterised as a syndrome rather than a disease)
  • Functional ovarian hyperandrogenism
  • Hyperandrogenic chronic anovulation
  • Ovarian dysmetabolic syndrome

Definition

There are two definitions that are commonly used:

  1. In 1990 a consensus workshop sponsored by the NIH/NICHD suggested that a patient has PCOS if she has (1) signs of androgen excess (clinical or biochemical), (2) oligoovulation, and (3) other entities are excluded that would cause polycystic ovaries.
  2. In 2003 a consensus workshop sponsored by ESHRE/ASRM in Rotterdam indicated PCOS to be present if 2 out of 3 criteria are met: (1) oligoovulation and/or anovulation, (2) excess androgen activity, (3) polycystic ovaries (by gynecologic ultrasonography), and other causes of PCOS are excluded.

The Rotterdam definition is wider, including many more patients, notably patients without androgen excess, while in the NIH/NICHD definiton androgen excess is a prerequisite. Critics maintain that findings obtained from the study of patients with androgen excess cannot be necessarily extrapolated to patients without androgen excess.

Signs and symptoms

Common symptoms of PCOS include:

  • Oligomenorrhea, amenorrhea - irregular/few, or absent, menstrual periods; cycles that do occur may comprise heavy bleeding (check with a gynaecologist, since heavy bleeding is also an early warning sign of endometrial cancer, for which women with PCOS are at higher risk)
  • Infertility, generally resulting from chronic anovulation (lack of ovulation)
  • Elevated serum (blood) levels of androgens (male hormones), specifically testosterone, androstenedione, and dehydroepiandrosterone sulfate (DHEAS), causing hirsutism and occasionally masculinization
  • Central obesity - "apple-shaped" obesity centered around the lower half of the torso
  • Androgenic alopecia (male-pattern baldness)
  • Acne / oily skin / seborrhea
  • Acanthosis nigricans (dark patches of skin, tan to dark brown/black)
  • Acrochordons (skin tags) - tiny flaps of skin
  • Prolonged periods of PMS-like symptoms (bloating, mood swings, pelvic pain, backaches)
  • Sleep apnea

Signs are:

  • Multiple cysts on the ovaries. Sonographycally they may present as a "string of pearls".
  • Enlarged ovaries, generally 1.5 to 3 times larger than normal, resulting from multiple cysts
  • Thickened, smooth, pearl-white outer surface of ovary
  • Chronic pelvic pain, possibly due to pelvic crowding from enlarged ovaries; however, the actual cause is not yet known
  • The ratio of LH (Luteinizing hormone) to FSH (Follicle stimulating hormone) is 2:1 or more, particularly in the early phase of the menstrual cycle.
  • Increased levels of testosterone.
  • Decreased levels of sex hormone binding globulin.
  • Hyperinsulinemia.

Read more at Wikipedia.org


[List your site here Free!]


Metformin for polycystic ovary syndrome - Tips from Other Journals
From American Family Physician, 12/1/03 by Anne D. Walling

Polycystic ovary syndrome (PCOS), a combination of oligomenorrhea or anovulation with hyperandrogenism, affects approximately 5 to 7 percent of women of reproductive age. This neuroendocrine abnormality may be caused by elevated luteinizing hormone (LH) levels and more frequent pulses of LH secretion. Women with hyperandrogenism also have increased insulin resistance, which manifests as increased body mass index (BMI), increased waist-to-hip ratio or, in severe cases, acanthosis nigricans. The combination of severe insulin resistance and LH stimulation results in increased ovarian secretion of testosterone, leading to the virilizing features of PCOS. The syndrome should be suspected in women with hirsutism, irregular menstruation, or infertility. Traditional treatment involves the use of clomiphene therapy and weight loss for subfertility, and combination oral contraceptives plus spironolactone for hirsutism. Barbieri conducted a review of the increasing role of insulin sensitizers, such as metformin, in the effective treatment of women with PCOS.

From more than 90 articles on metformin and PCOS, the author identified 21 studies that reported clinical outcomes or significant aspects of the clinical pharmacology of metformin related to PCOS. Metformin does not produce hypoglycemia but is thought to act on several cellular processes, including hepatic glucose production, intestinal absorption of glucose, gluconeogenesis, and the use of insulin-mediated glucose in peripheral tissues.

In one large clinical trial of 3,234 adults with elevated fasting and postglucose-load plasma glucose concentrations, metformin reduced the risk of progression to diabetes by 31 percent compared with placebo. Even greater reductions were achieved with the addition of aggressive lifestyle modifications. The author emphasizes the need for both lifestyle changes and metformin therapy to reduce the risk of diabetes in women with PCOS.

Metformin also is effective in achieving weight loss in women with PCOS. It potentiates the low-calorie diets typically used to achieve the BMI of 20 to 25 kg per m2 that is necessary for the return of ovulation. In one study of 150 obese women, a 10 percent reduction in BMI was achieved with metformin therapy. In another study, metformin plus a low-calorie diet was superior to the low-calorie diet alone for weight loss in women with PCOS. The weight loss action of metformin appears to be caused by the reduction in insulin resistance as well as by appetite suppression. Metformin is the only antidiabetic agent associated with weight loss rather than weight gain and is, thus, particularly suitable for therapy in patients with PCOS.

The effects of metformin on menstrual function and infertility may be caused by decreased insulin resistance and lowered testosterone levels. In a long-term study of 23 women with PCOS, one half of those treated with metformin resumed regular menstruation. The effect appears to increase with duration of treatment. Studies of women who were treated for at least six months report that more than 90 percent of women resumed regular menstruation. Four to six months of therapy are thought to be necessary for ovulation to commence. The effect of metformin on hirsutism has not been extensively reported, and androgen-blocking drugs may be more effective than metformin for treatment of this symptom.

In studies, about 5 percent of patients discontinued metformin therapy because of side effects, but more than one half of patients reported diarrhea, and one fourth experienced other gastrointestinal upsets. A rare but potentially serious side effect is lactic acidosis in patients with renal insufficiency. Metformin also may interact with medications such as cimetidine, digoxin, amiloride, quinidine, vancomycin, and trimethoprim, and may interfere with vitamin B12 absorption.

The author concludes that metformin in dosages of 1,500 to 2,550 mg per day addresses the major aspects of PCOS management and is expected to become more widely used to treat this syndrome. Because of the gastrointestinal side effects of metformin, the usual starting dosage is 500 mg taken with the largest meal of the day. If tolerated, the dosage is gradually increased to 500 mg with each meal. Clinical effect does not usually occur at dosages of less than 1,000 mg per day, and the optimal effect may not be apparent for several months.

Anne D. Walling, M.D.

Barbieri RL. Metformin for the treatment of polycystic ovary syndrome. Obstet Gynecol April 2003;101;785-93.

COPYRIGHT 2003 American Academy of Family Physicians
COPYRIGHT 2003 Gale Group

Return to Polycystic ovarian syndrome
Home Contact Resources Exchange Links ebay